Answers are grounded in this paper and cite their sources.
Living donor kidney transplantation (LDKT) is the best treatment for kidney failure, offering substantial benefits to patients with kidney disease, the healthcare system, and society. Recognition of these important benefits is leading to new initiatives to increase access to LDKT, including better education of kidney patients on the benefits of LDKT, strategies for identifying potential donors, and mitigation of barriers to living donors—including the focus on increasing LDKT outlined in the recent US “Advancing American Kidney Health” Executive Order.1 In this context, it is critical to prioritize maintaining and advancing living donor safety, grounded in evidence-based evaluation strategies, transparent risk assessment, efficiency, and long-term follow-up. In a new article, Claisse et al offer a timely review of living kidney donor evaluation practices, focused on comparing existing guidelines since 2010 with regard to individual characteristics and medical conditions at donation.2 The authors also describe and critique the approach of the 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline for integrated risk assessment based on the donor candidate’s profile of demographic and health factors3 and focus on the measurement and application of glomerular filtration rate (GFR) in candidate evaluation and selection. The authors favor GFR measurement with a reference method and application of age-specific thresholds to define acceptable levels of GFR for donor candidate approval. As coauthors of the 2017 KDIGO living donor guideline, we applaud the work of Claisse et al in providing a contemporary review of key health factors considered in the living donor evaluation. We agree with the authors’ premise that “Dealing with a paradigm shift like the one proposed by the KDIGO should not be seen as a revolution but rather a smooth and necessary evolution.” We acknowledge the ethical principle of nonmaleficence (“do no harm”) and that current risk-based estimates are imperfect—probably more for younger than older donor candidates. We also acknowledge that reasonable thresholds for “very low” and “very high” exist for many parameters, but in between, decision-making is most complex. However, we are concerned that persistent reliance on single thresholds for multiple parameters, rather than an integrated approach using personalized risk estimates, may result in declining acceptable candidates and approving unacceptable ones. As an example, we consider their proposal to determine donor candidacy based on age-adapted predonation GFR thresholds rather than the risk-based approach recommended by KDIGO. The overarching rationale for an integrated risk-based approach recommended by KDIGO includes: (1) balancing ethical principles of autonomy and justice versus nonmaleficence, which requires consistent decision-making for all donor candidates; (2) Supporting consistent, transparent decision-making by integrating multiple parameters into absolute risk estimates for use in selection decisions, to avoid the inconsistencies that may result from considering individual parameters in isolation (ie, relative risk thresholds for individual parameters). The rationale for use of an integrated risk-based approach rather than age-specific GFR thresholds includes that age-specific thresholds are based on a concept of “normal GFR for age,” which has not been shown to be related to postdonation outcomes. Selection decisions based on age-specific thresholds also assume greater accuracy of measured GFR (mGFR) than currently exists, even with reliable methods, such as plasma clearance of iohexol used by the authors. For these reasons, we are concerned that strict application of age-specific mGFR thresholds, without consideration of integrated risk assessment (eg, using a combination of the predonation tool developed in the guideline, based on healthy nondonors, that estimates risk if the individual does not donate, and a recent postdonation tool, based on actual donors, that estimates risk if the individual does donate4), may result in inconsistent decisions from the perspective of long-term kidney failure risk. With regard to the approach for assessing GFR, the accuracy of urinary or plasma clearance of an exogenous filtration marker exceeds that of measured creatinine clearance (mClcr) or estimated GFR (eGFR), but the time and cost of these more accurate procedures are also higher.5 GFR measurement methods are not standardized across transplant centers and measurement error is an important concern.6 The accuracy of radionuclide imaging is usually lower than urinary or plasma clearance methods.7 The assertion of Claisse et al that “the KDIGO guidelines consider the eGFR to be sufficient” is not fully representative of our intent. Recognizing the limitations of eGFR, the guideline recommends initial eGFR from serum creatinine (eGFRcr), followed by confirmatory testing using one or more of the following depending on availability: mGFR, mClcr, eGFR from the combination of serum creatinine and cystatin C (eGFRcr-cys) or repeated eGFRcr. The latter (repeated eGFRcr) is recommended only if all of the former are unavailable, but was included to address the spectrum of testing availability, given that KDIGO is an international guideline. An important barrier to living donation not discussed in the review by Claisse et al is posed by inefficiencies in the donor candidate evaluation process.8 Delays can lead to dialysis initiation for preemptive transplant candidates, longer time on dialysis, and reduced donor satisfaction.8 The 2017 KDIGO guideline recommends that transplant programs conduct efficient donor evaluations, meeting the needs of donor candidates, intended recipients, and the transplant program.3 Opportunities to improve efficiency include the choice, timing, and sequence of evaluation tests and visits, the use of navigators, and monitoring of evaluation timeliness as a quality metric. Streamlining the assessment of GFR affords an opportunity to optimize efficiency. To support the KDIGO guideline approach, a web-based calculator was developed to compute posttest probabilities for measured GFR above or below thresholds for decision-making (http://ckdepi.org/equations/donor-candidate-gfr-calculator/).9 A strategy to optimize efficiency may include obtaining eGFRcr and eGFRcr-cys before a donor candidate’s visit to the center to determine the posttest probability that mGFR is <60 mL/min per 1.73 m2. Donor candidates with a very high-posttest probability of mGFR below 60 mL/min per 1.73 m2 could be excluded rather than undergo a complete evaluation (Figure 1). Alternatively, donor candidates with posttest probability in an intermediate range—or in jurisdictions such as the United States where mClcr or mGFR is required—would undergo confirmatory tests with mGFR or mClcr. This approach may improve efficiency by allowing early exclusion of likely ineligible donor candidates and planning for confirmatory tests when necessary.FIGURE 1.: Assessment of GFR and application to donor candidate selection. Reproduced with permission from (Garg et al10). eGFR, estimated GFR; GFR, glomerular filtration rate; mGFR, measured GFR.Accurate and efficient assessment of risk in the living donor candidate evaluation—with long-term kidney failure risk as a central consideration—supports expanding living kidney donation within a defensible system of practice. Currently, available tools for integrated, absolute risk assessment3,4 are not perfect, but mark important progress in advancing a framework for consistent, transparent decision-making that can and should be updated with evolving evidence. Empirical studies including formal evaluations of risk projection, risk communication, and practice efficiency are feasible and necessary to advance the evidence base grounding the practice of living donation and living donor transplantation. While important progress has been made, ongoing efforts are vital in honoring the life-saving gift of living donors and in supporting more opportunities for healthy, willing persons to safely give the gift of life to patients in need.
No takes yet. Share an insight, caveat, or question.
Lentine et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: